In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.41 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Agilent Technologies (A) boosts its LSAG segment with the launch of the Agilent InfinityLab Liquid Chromatography (LC) Series portfolio, comprising the 1290 Infinity III LC, 1260 Infinity III Prime LC and 1260 Infinity III LC systems.The new Agilent InfinityLab Assist Technology is being used for the first time in these High Performance Liquid Chromatography systems, providing enhanced system assistance.These systems have a significant impact on task automation, connectivity, predictive feedback and error r ...

Core Insights - Agilent Technologies reported Q3 fiscal 2024 earnings of $1.32 per share, exceeding estimates by 5.6%, but down 8% year-over-year [2] - Revenues reached $1.58 billion, surpassing the consensus estimate of $1.56 billion, but declined 5.6% year-over-year [2] - The company faced broad-based weakness across several markets, including Pharma, Food, Chemical, and Academic sectors, with weak momentum in China [2] Financial Performance - Life Sciences & Applied Markets Group (LSAG) generated $782 million, down 8% year-over-year, missing the consensus estimate of $849 million [3] - Agilent Cross Lab Group (ACG) revenues were $411 million, exceeding the consensus of $385 million, with a 4% year-over-year increase [3] - Diagnostics and Genomics Group (DGG) revenues decreased 9% year-over-year to $385 million, beating the consensus of $332 million [4] Operating Results - Gross margin for LSAG expanded by 10 basis points to 60.2%, while ACG's gross margin increased by 120 basis points to 52.1% [5] - DGG's gross margin contracted by 170 basis points to 51.8% [5] - Operating margin for Q3 was 21.1%, significantly up from 7.9% in the prior year [5][6] Balance Sheet - As of July 31, 2024, cash and cash equivalents were $1.78 billion, up from $1.67 billion in April 2024 [7] - Accounts receivables were $1.23 billion, slightly down from $1.25 billion in the previous quarter [7] - Long-term debt remained stable at $2.137 billion [7] Guidance - For Q4 fiscal 2024, management expects revenues between $1.641 billion and $1.691 billion, indicating a potential decline of 2.8% to an increase of 0.2% year-over-year [8] - Fiscal 2024 revenue guidance revised to $6.45-$6.50 billion, reflecting a decline of 5.6-4.9% year-over-year [8] - Non-GAAP earnings per share guidance for fiscal 2024 adjusted to $5.21-$5.25 [8] Market Sentiment - Recent estimates for Agilent have been trending downward, indicating a shift in market sentiment [9] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [11]

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields. While its many segments are experiencing pullbacks in the end market, its top growth segment is being driven by solutions to address polyfluoroalkyl substances (PFAS), otherwise known as forever chemicals ...

In this articleAIR-FRAGEBAAALTULSA, Okla. — Parts and labor shortages. Delayed deliveries of new airplanes from Boeing and Airbus. An engine recall. Premature repairs. It's all piling up, and aircraft engine shops around the world are overflowing. As travelers boarded planes in record numbers this summer, airline executives waited anxiously for repairs and overhauls of their engines.The repair and overhaul of engines has swelled from a $31 billion business before the pandemic to $58 billion this year, accor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended July 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For transition period from to Commission File Number: 001-15405 AGILENT TECHNOLOGIES, INC. (Exact Name of registrant as specified in its charter) Delaware 77-0518772 (State or other jurisd ...

Have you assessed how the international operations of Agilent Technologies (A) performed in the quarter ended July 2024? For this scientific instrument maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become es ...

hapabapa Agilent Technologies (NYSE:A) offers instruments, consumables, software and services to life sciences, diagnostics and applied chemical markets. Agilent has made significant efforts in transforming its business towards growth areas including biopharma, polyfluoroalkyl substances (PFAS) testing and advanced materials for semiconductor. I am initiating a ‘Buy’ rating with a one-year target price of $160 per share. Growing Biopharma, PFAS & Advanced Materials Agilent offers workflow solutions for ...

Agilent Technologies (A) has delivered third-quarter fiscal 2024 earnings of $1.32 per share, which beat the Zacks Consensus Estimate by 5.6%. However, the bottom line decreased 8% from the year-ago quarter. Revenues of $1.58 billion beat the Zacks Consensus Estimate of $1.56 billion. The top line declined 5.6% on a reported basis and 4.4% on a core basis from the year-ago quarter. The decline was attributed to broad-based weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and G ...

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%. Adjusted EPS of $1.32 surpassed the street view of $1.26.Agilent said it sees fourth-quarter revenue of $1.641 billion – $1.691 b ...